Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Merck, Gilead Sciences, and Novartis all offer generous dividend yields. These companies all have underrated growth prospects in the long run. At low valuations, they can be no-brainer buys for ...

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% ...

The company should continue doing what it has done for a while: develop innovative drugs, deliver strong financial results, and reward investors with dividend hikes. That's why Gilead Sciences is ...